Last checked at 15 Jan 2020 07:00
genedrive plc
("genedrive" or the "Company")
Notice of Results
genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces it will release its interim results for the six months ended 31 December 2019 on Tuesday, 4 February 2020.
For further details please contact:
genedrive plc | www.genedriveplc.com | |
David Budd: CEO / Matthew Fowler: CFO | +44 (0)161 989 0245 | |
Peel Hunt LLP | +44 (0)20 7418 8900 | |
James Steel / Oliver Jackson | ||
Stanford Capital Partners Limited | +44 (0)20 3815 8880 | |
Patrick Claridge / John Howes | ||
Walbrook PR Ltd (Media Relations & Investor Relations) | +44 (0)20 7933 8780 or genedrive@walbrookpr.com | |
Paul McManus / Anna Dunphy | +44 (0)7980 541 893 / +44 (0)7876 741 001 | |
Notes to Editors
About genedrive plc
genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® mt-RNR1-ID kit has received CE-IVD Certification and will be launched into Europe and other markets following full evaluation by the UK National Health Service. The Company has assays on market for the detection of HCV, certain military biological targets, and has tests in development for tuberculosis (mTB).
Further details can be found at: www.genedriveplc.com and www.genedrive.com.